I-Mab Biopharma
A global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology.
I-Mab’s innovative pipeline is driven by internal R&D’s Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. Founded in 2016, the company has offices in the USA and China.
Latest I-Mab Biopharma News & Features
7 June 2024
8 February 2024
25 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze